Compare KRYS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | PRAX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.3B |
| IPO Year | 2017 | 2020 |
| Metric | KRYS | PRAX |
|---|---|---|
| Price | $327.51 | $288.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $392.11 | ★ $638.68 |
| AVG Volume (30 Days) | 204.3K | ★ 357.8K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 3.62 | N/A |
| Revenue | ★ $389,130,000.00 | N/A |
| Revenue This Year | $31.33 | N/A |
| Revenue Next Year | $27.55 | $39,590.54 |
| P/E Ratio | $93.08 | ★ N/A |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $179.16 | $50.31 |
| 52 Week High | $382.54 | $392.70 |
| Indicator | KRYS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 35.63 |
| Support Level | $331.79 | $282.35 |
| Resistance Level | $371.16 | $354.17 |
| Average True Range (ATR) | 9.85 | 14.63 |
| MACD | -1.37 | -1.65 |
| Stochastic Oscillator | 17.44 | 21.96 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.